CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Class A	Common Class B	Application of amended leasing guidance	Common Stock Common Class A	Common Stock Common Class B	Additional Paid-in Capital	Retained Earnings (Accumulated Deficit)	Retained Earnings (Accumulated Deficit) Application of amended leasing guidance	Accumulated Other Comprehensive Income (Loss)
Beginning Balance (in shares) at Dec. 31, 2018					137,180,213	4,045,199
Beginning Balance at Dec. 31, 2018	$ 1,334,260			$ 4,719	$ 1,372	$ 40	$ 1,693,512	$ (360,664)	$ 4,719	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(420,212)							(420,212)
Compensation expense related to granting of stock awards (in shares)					1,631,529
Compensation expense related to granting of stock awards	13,382				$ 16		13,366
Issuance of common stock related to the ESPP (in shares)					334,782
Issuance of common stock related to the ESPP	1,329				$ 4		1,325
Exercise of stock options (in shares)					180,300
Exercise of stock options	$ 244				$ 2		242
Common stock repurchase (in shares)	(5,000,000)				(5,000,000)
Common stock repurchase	$ (18,340)				$ (50)		(18,290)
Purchase of vested employee restricted stock units (in shares)	(459,000)				(459,203)
Purchase of vested employee restricted stock units	$ (2,905)				$ (5)		(2,900)
Payment of dividends on common stock	(31,474)						(31,474)
Dividend equivalents, net of forfeitures	579							579
Net unrealized gain (loss) on derivatives	(139)									(139)
Ending Balance (in shares) at Dec. 31, 2019					133,867,621	4,045,199
Ending Balance at Dec. 31, 2019	881,443				$ 1,339	$ 40	1,655,781	(775,578)		(139)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(242,224)							(242,224)
Compensation expense related to granting of stock awards (in shares)					3,389,801
Compensation expense related to granting of stock awards	11,134				$ 34		11,100
Issuance of common stock related to the ESPP (in shares)					165,756
Issuance of common stock related to the ESPP	$ 240				$ 1		239
Common stock repurchase (in shares)	0
Purchase of vested employee restricted stock units (in shares)	(510,000)				(509,803)
Purchase of vested employee restricted stock units	$ (1,527)				$ (5)		(1,522)
Payment of dividends on common stock	(3,443)						(3,443)
Dividend equivalents, net of forfeitures	765							765
Net unrealized gain (loss) on derivatives	(1,650)									(1,650)
Ending Balance (in shares) at Dec. 31, 2020		136,913,375	4,045,199		136,913,375	4,045,199
Ending Balance at Dec. 31, 2020	644,738				$ 1,369	$ 40	1,662,155	(1,017,037)		(1,789)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(3,572)							(3,572)
Compensation expense related to granting of stock awards (in shares)					3,226,962
Compensation expense related to granting of stock awards	11,185				$ 32		11,153
Issuance of common stock related to the ESPP (in shares)					106,049
Issuance of common stock related to the ESPP	$ 316				$ 1		315
Exercise of stock options (in shares)	200,000				199,972
Exercise of stock options	$ 86				$ 2		84
Common stock repurchase (in shares)	0
Purchase of vested employee restricted stock units (in shares)	(386,000)				(386,003)
Purchase of vested employee restricted stock units	$ (2,066)				$ (3)		(2,063)
Payment of dividends on common stock	(449)						(449)
Dividend equivalents, net of forfeitures	467							467
Net unrealized gain (loss) on derivatives	1,500									1,500
Ending Balance (in shares) at Dec. 31, 2021		140,060,355	4,045,199		140,060,355	4,045,199
Ending Balance at Dec. 31, 2021	$ 652,205				$ 1,401	$ 40	$ 1,671,195	$ (1,020,142)		$ (289)